Featured Story | By Annalee Armstrong MaaT Pharma is not getting out from under an FDA clinical hold for its microbiome drug any time soon. MaaT013, in development for steroid-resistant acute graft-versus-host disease (aGvHD), was placed on hold a year ago, halting a phase 3 trial in the U.S. read more |
| |
|---|
|
Top Stories By Dave Muoio The two major players will lean on HCA's wealth of patients and nurses as they seek to tackle multiple sore spots for the healthcare industry. read more By Fraiser Kansteiner The potential cancer agent Nitroso-STG-19, also known as NTTP, has surfaced in certain samples of Merck & Co.’s Type 2 diabetes blockbuster Januvia, the FDA said Tuesday. Januvia, also known as sitagliptin, generated $5.3 billion in 2021 and ranked as Merck’s third best-selling drug behind Keytruda and Gardasil. read more By Conor Hale The collaboration will see the medtech giant and Labcorp’s drug development division partner up with Big Pharma companies, with the goal of offering an end-to-end solution that spans the development, approval and distribution of diagnostic tests. read more By Max Bayer Bristol Myers Squibb is sold on GentiBio's engineered T-cell therapy, betting $1.9 billion on up to three programs. The deal comes a year after GentiBio hauled in more than $150 million in series A funds. read more By Angus Liu Bristol Myers Squibb is trumpeting a first-in-class win as it tries to move Abecma up in the line of multiple myeloma treatment. But it may wind up one step behind Johnson & Johnson and Legend Biotech in terms of treatment order. read more By Paige Minemyer The settlement agreement ends a decade-long legal battle that stems from a 2012 class action suit alleging Blues plans would split up geographic areas to avoid competing with one another directly. read more By Andrea Park The RespiPoints program initially launched in 2016 with support for Spiriva Respimat, one of Boehringer’s inhaler-based prescription treatments for symptoms of COPD. read more By Kevin Dunleavy New Catalent CEO Alessandro Maselli has pulled off his first key acquisition, a $475 million buyout of Metrics Contract Services. The CDMO, a subsidiary of Australia-based Mayne Pharma Group, has a 333,000-square-foot plant in Greenville, N.C., with the capacity to produce more than 1 billion solid-dose pills annually. read more By Nick Paul Taylor Disc Medicine has secured cash to advance hematology assets picked up from AbbVie and Roche, inking a merger with the floundering Gemini Therapeutics and tapping a starry syndicate of VCs to extend its runway into 2025. read more By Conor Hale The California-based outfit went through Chapter 11 bankruptcy proceedings in early 2020 and re-emerged as a private enterprise after about a decade as a publicly traded company. read more By Anastassia Gliadkovskaya Walmart is not accepting prescriptions for controlled substances written via telehealth without an in-person visit in the preceding 24 months, implicating virtual addiction treatment. Corporate policies that limit telehealth prescriptions “are a threat to patient safety and recovery,” said Anna Legreid Dopp with the American Society of Health-System Pharmacists. read more By Gabrielle Masson Vyne Therapeutics’ lead asset has failed to improve the severity of mild-to-moderate atopic dermatitis, uprooting the biotech’s plans and sending the stock plummeting. read more By Andrea Park Saama's Life Science Analytics Cloud is powered by cloud computing and machine learning artificial intelligence technologies, the latter of which was trained using more than 100 million clinical data points. read more Resources Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 
